Axcella Health Inc. (AXLA): Price and Financial Metrics
GET POWR RATINGS... FREE!
AXLA Stock Price Chart Interactive Chart >
AXLA Price/Volume Stats
|Current price||$1.96||52-week high||$5.90|
|Prev. close||$1.95||52-week low||$1.35|
|Day high||$1.97||Avg. volume||79,011|
|50-day MA||$2.04||Dividend yield||N/A|
|200-day MA||$2.44||Market Cap||103.05M|
Axcella Health Inc. (AXLA) Company Bio
Axcella Health Inc., a biotechnology company, researches and develops novel multifactorial interventions to support health and address dysregulated metabolism in the United States. The company develops its products based on its AXA Development Platform. It offers AXA1665 for use in treating hepatic encephalopathy; AXA1125 and AXA1957 to treat non-alcoholic fatty liver disease; AXA2678 for use in treating immobilization-induced acute muscle atrophy; and AXA4010 to target multiple biological pathways.
Most Popular Stories View All
AXLA Latest News Stream
|Loading, please wait...|
AXLA Latest Social Stream
View Full AXLA Social Stream
Latest AXLA News From Around the Web
Below are the latest news stories about Axcella Health Inc that investors may wish to consider to help them evaluate AXLA as an investment opportunity.
In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Axcella Health (AXLA – Research Report), with a price target of $10.00. The company's shares closed last Monday at $1.67, close to its 52-week low of $1.44. According to TipRanks.com, LeBoyer is a 4-star analyst with an average return of 19.9% and a 33.0% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Cocrystal Pharma, and Imugene Limited. Currently, the analyst consensus on Axcella Health is a Strong Buy with an average price target of $11.75, which is a 563.8% upside from current levels.
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Axcella Health (AXLA – Research Report) yesterday and set a price target of $14.00. The company's shares closed last Monday at $1.67, close to its 52-week low of $1.44. According to TipRanks.com, Arce is a 5-star analyst with an average return of 14.0% and a 39.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Aurinia Pharmaceuticals, and Galmed Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axcella Health with a $12.33 average price target.
Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors.
CAMBRIDGE, Mass., February 14, 2022--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that the U.S. Food and Drug Administration (FDA) has granted a Fast Track Designation to AXA1125 for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. AXA1125 is a multi-targeted oral drug candidate that is currently being
CAMBRIDGE, Mass., February 10, 2022--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that company management will be participating in the SVB Leerink Global Healthcare Conference.
AXLA Price Returns